2022 ACOG Annual Clinical & Scientific Meeting

Several studies presented at ACOG 2022 have raised the question as to whether postpartum depression (PPD) is one of the mental health outcomes of the COVID-19 pandemic.

Combination therapy with relugolix (once daily relugolix 40 mg, estradiol 1 mg, norethindrone acetate 0.5 mg) leads to improvement in heavy menstrual bleeding (HMB) and in other uterine fibroid (UF)-related symptoms independent of the location of the largest fibroid, results of a recent study have shown.

There appears to be a dearth of evidence on the management of nonrelaxing pelvic floor dysfunction (PFD), a debilitating condition characterized by tension of the pelvic floor muscles that frequently leads to pelvic pain, according to data presented at ACOG 2022.

Administering mifepristone and misoprostol in the emergency departments (EDs) appears to be effective, increasing the availability of early pregnancy loss medical management services to women during the COVID-19 pandemic in the US, as shown in a study presented at the 2022 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting.

Acceptance rates of COVID-19 vaccines have remained unchanged among unvaccinated pregnant women following national recommendations, with nearly one-third of patients seeing the vaccine as something harmful to their pregnancy, according to a study.